WS Investor
20 Nov 2025, 18:08
Dexcom to launch G7 15 Day continuous glucose monitoring system in the U.S. on December 1
DexCom announced that its new Dexcom G7 15 Day CGM system will launch in the United States on December 1, offering real-time glucose tracking for an extended 15.5-day wear period. The system will initially be available through durable medical equipment providers and will be covered for Medicare beneficiaries, meeting CMS requirements for therapeutic CGM devices.
The updated sensor provides longer wear, reduced waste, and maintains Dexcom’s accuracy with an overall MARD of 8.0%. Users keep all G7 features, including Apple Watch direct-to-watch connectivity, automated activity and meal logging, Clarity data integration, and remote sharing with caregivers. At launch, the 15 Day model will integrate with iLet Bionic Pancreas and Omnipod 5, with Tandem compatibility expected soon.
Dexcom said the extended-wear version responds to user demand for fewer sensor changes while preserving reliability and performance.
DexCom announced that its new Dexcom G7 15 Day CGM system will launch in the United States on December 1, offering real-time glucose tracking for an extended 15.5-day wear period. The system will initially be available through durable medical equipment providers and will be covered for Medicare beneficiaries, meeting CMS requirements for therapeutic CGM devices.
The updated sensor provides longer wear, reduced waste, and maintains Dexcom’s accuracy with an overall MARD of 8.0%. Users keep all G7 features, including Apple Watch direct-to-watch connectivity, automated activity and meal logging, Clarity data integration, and remote sharing with caregivers. At launch, the 15 Day model will integrate with iLet Bionic Pancreas and Omnipod 5, with Tandem compatibility expected soon.
Dexcom said the extended-wear version responds to user demand for fewer sensor changes while preserving reliability and performance.
